These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 25845131)

  • 1. Factors that affect rate of INR decline after warfarin discontinuation.
    Burmester JK; Berg RL; Schmelzer JR; Mazza JJ; Yale SH
    WMJ; 2015 Feb; 114(1):16-20. PubMed ID: 25845131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
    Tsu LV; Dienes JE; Dager WE
    Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Search for predictors of nontherapeutic INR results with warfarin therapy.
    McGriff-Lee NJ; Csako G; Chen JT; Dang DK; Rosenfeld KG; Cannon RO; Macklin LR; Wesley RA;
    Ann Pharmacother; 2005 Dec; 39(12):1996-2002. PubMed ID: 16288081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
    Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
    Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy.
    Huynh TK; Costello JL; Rebuck JA
    Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.
    Schultz KT; Bungard TJ
    Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
    Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
    Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation.
    Pengo V; Banzato A; Garelli E; Zasso A; Biasiolo A
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):739-41. PubMed ID: 8292723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin.
    Kim JS; Jongnarangsin K; Latchamsetty R; Chugh A; Ghanbari H; Crawford T; Yokokawa M; Good E; Bogun F; Pelosi F; Morady F; Oral H
    Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):302-9. PubMed ID: 23443620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation of a method to predict fresh-frozen plasma dosage in anticoagulated patients.
    Frazee LA; Bourguet CC; Gutierrez W; Elder-Arrington J; Elackattu AE; Haller NA
    Am J Ther; 2008; 15(2):111-8. PubMed ID: 18356630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy.
    Dowd MB; Kippes KA; Witt DM; Delate T; Martinez K
    Thromb Res; 2012 Aug; 130(2):152-6. PubMed ID: 22221937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.
    Wong YM; Quek YN; Tay JC; Chadachan V; Lee HK
    J Clin Pharm Ther; 2011 Oct; 36(5):585-91. PubMed ID: 21070296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.
    Goto T; Miura M; Murata A; Terata K; Uno T; Yamamoto K; Abe Y
    Clin Chim Acta; 2010 Sep; 411(17-18):1375-7. PubMed ID: 20420818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemorrhagic events lead to an increase in international normalized ratio in patients on warfarin.
    Perona S; Ford M; Rindone J
    J Pharm Pract; 2011 Oct; 24(5):494-7. PubMed ID: 22156711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the chromogenic factor X assay in patients transitioning from argatroban to warfarin therapy.
    Austin JH; Stearns CR; Winkler AM; Paciullo CA
    Pharmacotherapy; 2012 Jun; 32(6):493-501. PubMed ID: 22511112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.